Actinium's ATNM — 400 Shows Antitumor Activity in Preclinical Lung Cancer Models

Actinium Pharmaceuticals reported preclinical antitumor activity for ATNM-400, its actinium-225 radiotherapy, across lung, colorectal and ovarian cancer models. In non-small cell lung cancer, ATNM-400 showed standalone activity and enhanced responses with KRAS or ALK inhibitors, including in resistant models. Colorectal cancer studies showed standalone activity and improved responses when ATNM-400 was combined with bevacizumab and oxaliplatin. Ovarian cancer models showed durable antitumor responses to ATNM-400 alone, including in bevacizumab-resistant tumors. The findings support broader solid-tumor development alongside ongoing clinical development in metastatic castration-resistant prostate cancer. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Actinium Pharmaceuticals Inc. published the original content used to generate this news brief via (Ref. ID: NY73952) on October 16, 2026, and is solely responsible for the informat